Despite mounting evidence suggesting a relationship between AD and metabolic disorders, it is not known to what extent the two hallmarks of the disease (amyloid and tau) contribute to peripheral or central metabolic abnormalities. This evidence concerns the gene MAPT and amyloidosis.